Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celgosivir in HCV Genotype 1 Non-Responders
NCT00217139Phase 2Completed
- Sponsor
- BioWest Therapeutics
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of celgosivir in hepatitis C (HCV) (3 arms), sponsored by BioWest Therapeutics. Primary endpoints: Safety analysis and HCV viral load. Started Sep 2005; status: completed.
02
Drugs
celgosivir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00217139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217139.